Wordt geladen...
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine
Naldemedine is a peripherally acting μ‐opioid‐receptor antagonist for the treatment of opioid‐induced constipation. Two phase 1 single‐dose studies investigated the pharmacokinetics and safety of a 0.2‐mg oral dose of naldemedine in subjects with renal impairment (mild, n = 9; moderate, n = 9; sever...
Bewaard in:
| Gepubliceerd in: | Clin Pharmacol Drug Dev |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7027783/ https://ncbi.nlm.nih.gov/pubmed/30977959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.690 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|